Total amount raised
$305.5 Million
Latest funding date
7/1/2026
Location
Scribe Therapeutics has successfully raised funds through multiple funding rounds, with the latest being an initial public offering in July 2026. The company is backed by ten investors, including Wellington Management.
What Is Scribe Therapeutics?
Scribe Therapeutics is a biotechnology company based in Alameda, California, specializing in developing CRISPR-based genetic medicines. The company aims to transform health outcomes by engineering safe and effective therapeutics that can alter genetic predispositions and improve health risks.
Founded by Benjamin Oakes, Scribe Therapeutics employs between 51-100 people. The company is involved in creating advanced gene-editing technologies to address various medical conditions and collaborates with leading pharmaceutical companies to broaden its therapeutic applications.
How Much Funding Has Scribe Therapeutics Raised?
- Series A
- Amount Raised: USD 20,000,000
- Date: October 2018
- Lead Investors: Andreessen Horowitz
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the development of their CRISPR-based genetic medicines.
- Series B
- Amount Raised: USD 100,000,000
- Date: March 2021
- Lead Investors: Avoro Capital Advisors, Avoro Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop the 'CRISPR by Design' platform and pipeline of breakthrough genetic medicines.
- Convertible Note
- Amount Raised: USD 30,000,000
- Date: May 2023
- Lead Investors: Prevail Therapeutics
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To secure additional funding for ongoing research and development.
- IPO
- Amount Raised: USD 148,000,000 (approximately; gross proceeds of the Nasdaq IPO of 9,867,000 shares at USD 15.00, including the underwriters' option to purchase 1,287,000 additional shares exercised in full, before underwriting discounts, commissions and offering expenses)
- Date: July 2026
- Lead Investors: Not applicable (initial public offering)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: Scribe says the net proceeds, with its existing cash and investments, will fund planned operating expenses and capital expenditures into the first half of 2029.
- Private Placement
- Amount Raised: USD 7,500,000 (gross proceeds; 500,000 shares of common stock sold to an affiliate of Sanofi at the USD 15.00 IPO price, concurrent with the IPO)
- Date: July 2026
- Lead Investors: Sanofi
- Valuation at Round: Not publicly disclosed
Total Amount Raised: USD 305,500,000. Current Valuation: Not publicly disclosed. Scribe's 10-Q also reports a USD 0.5 million Series A-2 in January 2019 and convertible notes that converted in October 2018; neither is listed or counted here.
Key Investors
- Sanofi
- Details: Sanofi is a global pharmaceutical company and a Scribe research collaborator. An affiliate of Sanofi bought all 500,000 shares in the private placement that closed alongside Scribe's July 2026 IPO.
- Investment Focus Areas: Pharmaceuticals, vaccines and strategic collaborations in genetic medicine
- Notable Investments: Scribe Therapeutics (Private Placement)
- Prevail Therapeutics
- Details: Prevail Therapeutics is a biotechnology company focused on developing gene therapies for neurodegenerative diseases. They aim to slow or stop the progression of these diseases by addressing their underlying genetic causes.
- Investment Focus Areas: Biotechnology, Gene Therapy, Neurodegenerative Diseases
- Notable Investments: Scribe Therapeutics (Convertible Note)
- Avoro Capital Advisors
- Details: Avoro Capital Advisors is an investment firm specializing in the healthcare sector. They provide capital to companies developing innovative medical treatments and technologies.
- Investment Focus Areas: Healthcare, Biotechnology, Pharmaceuticals
- Notable Investments: Scribe Therapeutics (Series B)
- Avoro Ventures
- Details: Avoro Ventures is a venture capital firm that invests in early-stage healthcare companies. They focus on supporting startups with the potential to make significant advancements in medical science.
- Investment Focus Areas: Healthcare, Biotechnology, Medical Devices
- Notable Investments: Scribe Therapeutics (Series B)
- Andreessen Horowitz
- Details: Andreessen Horowitz is a private venture capital firm based in Silicon Valley. They invest in technology companies across various stages, from seed to growth.
- Investment Focus Areas: Technology, Biotechnology, Software
- Notable Investments: Facebook, Airbnb, Scribe Therapeutics (Series A)
- Wellington Management
- Details: Wellington Management is a global investment management firm. They offer a broad range of investment solutions to clients worldwide, including mutual funds and institutional portfolios.
- Investment Focus Areas: Equities, Fixed Income, Alternatives
- Notable Investments: Moderna, Scribe Therapeutics
What's Next for Scribe Therapeutics?
With the March 2021 $100 million Series B financing, Scribe Therapeutics is positioned to expand its 'CRISPR by Design' platform, aiming to develop best-in-class in vivo therapies. This significant investment underscores the vast potential in treating a wide range of genetic diseases, positioning Scribe at the forefront of the biotechnology industry.
Future fundraising opportunities appear promising, as the successful Series B round sets a strong precedent. Continued advancements and strategic partnerships could attract further investment, propelling the company towards new milestones. However, Scribe may face challenges such as regulatory hurdles and competition in the rapidly evolving field of genetic medicine.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Scribe Therapeutics and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
